JP2007536260A5 - - Google Patents

Download PDF

Info

Publication number
JP2007536260A5
JP2007536260A5 JP2007511623A JP2007511623A JP2007536260A5 JP 2007536260 A5 JP2007536260 A5 JP 2007536260A5 JP 2007511623 A JP2007511623 A JP 2007511623A JP 2007511623 A JP2007511623 A JP 2007511623A JP 2007536260 A5 JP2007536260 A5 JP 2007536260A5
Authority
JP
Japan
Prior art keywords
sequence
genbank
seq
positions
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007511623A
Other languages
English (en)
Other versions
JP2007536260A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/015799 external-priority patent/WO2005107793A2/en
Publication of JP2007536260A publication Critical patent/JP2007536260A/ja
Publication of JP2007536260A5 publication Critical patent/JP2007536260A5/ja
Withdrawn legal-status Critical Current

Links

Description

図２９は、ＣＰＢ２時間後の尿ＮＧＡＬ濃度とＣＰＢ時間との相関を示す。
配列表の簡単な説明
本明細書に添付の配列表を、本発明の原理を説明するために引用し、本明細書の一部とする。
配列番号１はマウスＧＡＬ ｍＲＮＡ（Genbank NM_008491）のプライマー配列（フォワードプライマー、９３−１１２位）である。
配列番号２はマウスＧＡＬ ｍＲＮＡ（Genbank NM_008491）のプライマー配列（リバース、５７６−５５７位）である。
配列番号３はマウスβアクチンｍＲＮＡ（Genbank X03672）の配列（フォワード、４１５−４３４位）の例である。
配列番号４はマウスβアクチンｍＲＮＡ（Genbank X03672）の配列（リバース、６９６−６７７位）の例である。
JP2007511623A 2004-05-06 2005-05-06 虚血性および腎毒性障害の軽減および改善用ｎｇａｌ Withdrawn JP2007536260A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56864504P 2004-05-06 2004-05-06
US61556604P 2004-10-01 2004-10-01
PCT/US2005/015799 WO2005107793A2 (en) 2004-05-06 2005-05-06 Ngal for reduction and amelioration of ischemic and nephrotoxic injuries

Publications (2)

Publication Number Publication Date
JP2007536260A JP2007536260A (ja) 2007-12-13
JP2007536260A5 true JP2007536260A5 (ja) 2008-03-06

Family

ID=35320735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007511623A Withdrawn JP2007536260A (ja) 2004-05-06 2005-05-06 虚血性および腎毒性障害の軽減および改善用ｎｇａｌ

Country Status (6)

Country Link
US (5) US7776824B2 (ja)
EP (2) EP2661963B1 (ja)
JP (1) JP2007536260A (ja)
AU (1) AU2005240190C1 (ja)
CA (1) CA2565701A1 (ja)
WO (1) WO2005107793A2 (ja)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
CN102643818B (zh) * 2004-09-28 2014-04-09 夸克制药公司 寡核糖核苷酸以及其用于治疗脱发、肾衰竭和其它疾病的方法
ES2818028T3 (es) * 2004-12-20 2021-04-09 Antibodyshop As Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales
US20090305963A1 (en) * 2005-01-19 2009-12-10 Sukhatme Vikas P Lipocalin 2 for the Treatment, Prevention, and Management of Cancer Metastasis, Angiogenesis, and Fibrosis
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
US7825099B2 (en) * 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
JP4865377B2 (ja) 2006-03-28 2012-02-01 国立大学法人 新潟大学 ヒトメガリンの測定方法
US7662578B2 (en) 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
WO2007137584A1 (en) * 2006-05-30 2007-12-06 Antibodyshop A/S Methods and devices for rapid assessment of severity of injury
EP2064553B2 (en) * 2006-08-07 2023-06-07 Antibodyshop A/S Diagnostic test to exclude significant renal injury
WO2008060607A2 (en) 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
US8524462B2 (en) * 2006-11-14 2013-09-03 Alere San Diego, Inc. Methods and compositions for diagnosis and prognosis of renal artery stenosis
JP5128828B2 (ja) * 2007-02-16 2013-01-23 月桂冠株式会社 抗炎症剤及び抗酸化剤
US8313919B2 (en) 2007-03-21 2012-11-20 Bioporto Diagnostics A/S Diagnostic test for renal injury
EP2170403B1 (en) * 2007-06-27 2014-04-16 Quark Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of pro-apoptotic genes
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US8592170B2 (en) 2008-03-12 2013-11-26 The Trustees Of Columbia University In The City Of New York High molecular weight Ngal as a biomarker for chronic kidney disease
US8030097B2 (en) * 2008-04-30 2011-10-04 Versitech Limited and R & C Biogenius Limited Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
CA2724384A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
US20100122355A1 (en) * 2008-07-16 2010-05-13 Neal Paragas Transgenic Reporter Mouse and Method for Use
EP2330897A4 (en) * 2008-09-18 2013-11-27 Univ Columbia NGAL-BINDING SIDEROPHORES AND THEIR USE FOR THE TREATMENT OF IRON DEFICIENCY AND IRON SURPLUS
JP2012507723A (ja) * 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
WO2010058378A1 (en) * 2008-11-21 2010-05-27 Phadia Ab Methods, devices and kits for detecting or monitoring acute kidney injury
US20100233739A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction
US20100233740A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to distinguish kidney disease and predict mortality in subjects with cirrhosis
WO2010126055A1 (ja) * 2009-04-27 2010-11-04 国立大学法人新潟大学 腎障害の検出用マーカーとしての尿中メガリンの使用
JP5424702B2 (ja) 2009-04-27 2014-02-26 国立大学法人 新潟大学 尿中ヒトメガリンを測定することを含む腎疾患検出方法
EP2292284B1 (en) * 2009-09-04 2014-02-26 B. Braun Avitum AG Kidney substitution treatment machine
CN106995493B (zh) 2010-02-04 2021-09-24 卫材公司 氯毒素多肽和结合物及其应用
WO2011140554A1 (en) * 2010-05-07 2011-11-10 The Trustees Of Columbia University In The City Of New York Ngal and urinary tract infection
CN103097403B (zh) 2010-05-11 2017-04-19 弗雷德哈钦森癌症研究中心 氯毒素变体、缀合物及其使用方法
ES2667066T3 (es) 2010-05-24 2018-05-09 The Trustees Of Columbia University In The City Of New York Proteínas NGAL mutantes y usos de las mismas
WO2012042061A1 (en) * 2010-10-01 2012-04-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the progression and treating a chronic kidney disease in a patient
EP2697389A4 (en) * 2011-04-11 2014-09-10 Univ Columbia ABOUT OSTEOBLASTEN EXPRESSED LIPOCALIN 2 FOR THE ADJUSTMENT OF GLUCOSE COMPOUND CHANGES
WO2012167092A2 (en) * 2011-06-03 2012-12-06 The Regents Of The University Of Colorado, A Body Corporate Uses of and methods of treatment with cystathionine
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
BR112015013525A2 (pt) 2012-12-10 2017-11-14 Hutchinson Fred Cancer Res método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
DK3200582T3 (da) * 2014-09-29 2024-02-19 Fred Hutchinson Cancer Center Sammensætninger, kits og fremgangsmåder til induktion af erhvervet cytoresistens under anvendelse af stressproteininducere
JP5866053B1 (ja) * 2014-12-15 2016-02-17 株式会社ファンケル 皮膚粘弾性のマーカー及びその利用
EP3334498B1 (en) 2015-08-12 2023-06-07 The Trustees of Columbia University in the City of New York Methods of treating volume depletion and kidney injury
CN108290058B (zh) 2015-09-17 2023-05-16 美国安进公司 使用il23途径生物标志物预测il23拮抗剂的临床应答
CA3007097A1 (en) 2015-12-01 2017-06-08 Cornell University Use of mitochondrial iron chelators for treatment of chronic obstructive pulmonary disease
AU2016379157A1 (en) 2015-12-22 2018-06-21 Amgen Inc. CCL20 as a predictor of clinical response to IL23-antagonists
EP3184116B1 (en) * 2015-12-23 2020-09-16 National Taiwan Normal University Neutrophil gelatinase-associated lipocalin for use in prevention or treatment of polycystic kidney disease
TWI581802B (zh) * 2015-12-23 2017-05-11 國立臺灣師範大學 嗜中性白血球膠原蛋白質酶相關疏水性蛋白質之製藥用途
WO2017181149A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
CN110996985A (zh) * 2017-06-23 2020-04-10 Aki医疗有限公司 用于预防和治疗急性肾损伤的组合物
US11298564B2 (en) 2020-03-10 2022-04-12 Dennis M. Anderson Medical, surgical and patient lighting apparatus, system, method and controls with pathogen killing electromagnetic radiation
CN113075371B (zh) * 2021-03-22 2022-11-18 重庆医药高等专科学校 一种药物崩解仪

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU698350B2 (en) * 1995-04-12 1998-10-29 Oy Medix Biochemica Ab Methods and test kits for diagnosis of periodontal diseases and for predicting the risk of progression thereof
DE69735364T3 (de) 1996-05-24 2010-05-06 Biogen Idec Ma Inc., Cambridge Modulatoren für die regenerierung von gewebe
AUPP784398A0 (en) 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
US6114123A (en) 1999-06-14 2000-09-05 Incyte Pharmaceuticals, Inc. Lipocalin family protein
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
AU2003247303A1 (en) 2002-07-17 2004-02-02 Index Pharmaceuticals Ab Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders
AU2004225472B2 (en) 2003-03-27 2011-02-10 Children's Hospital Medical Center A method and kit for detecting the early onset of renal tubular cell injury
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury

Similar Documents

Publication Publication Date Title
JP2007536260A5 (ja)
JP2007508034A5 (ja)
JP2004538039A5 (ja)
JP2010524959A5 (ja)
JP2007075118A5 (ja)
JP2003515323A5 (ja)
JP2009528027A5 (ja)
JP2010227108A5 (ja)
JP2007119504A5 (ja)
HRP20090245T1 (en) Pyy agonists and uses thereof
JP2007518723A5 (ja)
WO2008005562A3 (en) Rna silencing compositions and methods for the treatment of huntington's disease
JP2006516098A5 (ja)
JP2010065037A5 (ja)
JP2009530811A5 (ja)
JP2020127437A5 (ja)
JP2005515404A5 (ja)
JP2007510403A5 (ja)
ATE431556T1 (de) Bestimmung von kurzkettiger srl- alkoholdehydrogenase (dhrs4) als biomarker für entzündungen und infektionen
JP2003160581A5 (ja)
WO2004082629A3 (en) Novel cyclosporins
JP2007523200A5 (ja)
JP2006522692A5 (ja)
CL2007003348A1 (es) Procedimiento de preparacion de 4,4'-(1-metil-1,2-etandiil)-bis-(2,6-piperazindiona); compuesto intermediario; procedimiento de preparacion y uso.
JP2005534326A5 (ja)